Physician profile
Jyothi Gudla
NPI 1194872713
$6,047.55
in general payments reported to CMS, 2019-2025
37 companies · $697 in 2025
The $697 reported for 2025 was more than what 85% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $909 · 2020: $894 · 2021: $934 · 2022: $1,143 · 2023: $822 · 2024: $648 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,074 · Education: $93.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,073.67 |
| Education | $93.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,554.13 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Acadia Pharmaceuticals INC | $1,199.82 | 2019-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $529.27 | 2019-2025 | Ingrezza |
| Eisai INC. | $291.72 | 2023-2025 | |
| Avanir Pharmaceuticals, INC. | $286.70 | 2019-2022 | |
| Astellas Pharma US INC | $269.94 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $231.11 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $178.46 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $176.62 | 2020-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $148.58 | 2023-2025 | Rexulti, Nuedexta |
| Astrazeneca Pharmaceuticals LP | $147.17 | 2019-2025 | Farxiga |
| Lilly USA, LLC | $138.83 | 2019-2023 | Amyvid |
| Sumitomo Pharma America, INC. | $98.63 | 2023 | Aptiom, Gemtesa |
| Insmed, INC. | $86.58 | 2025 | Arikayce |
| Janssen Pharmaceuticals, INC | $82.17 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $75.18 | 2025 | Watchman Access System |
| Lundbeck LLC | $59.22 | 2023-2025 | Rexulti |
| Abbvie INC. | $55.72 | 2023-2024 | |
| Sk Life Science, INC. | $49.38 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $41.97 | 2019 | |
| Neurelis, INC. | $39.35 | 2023 | Valtoco |
| Takeda Pharmaceuticals U.S.A., INC. | $34.76 | 2019 | |
| Melinta Therapeutics, LLC | $34.72 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.96 | 2024-2025 | |
| Urovant Sciences INC | $27.10 | 2021-2022 | |
| Abbott Laboratories | $22.61 | 2021 | |
| Kyowa Kirin, INC. | $19.01 | 2019 | |
| Cmp Pharma, INC. | $17.59 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.75 | 2022 | |
| Biogen, INC. | $14.54 | 2021 | |
| Mannkind Corporation | $14.20 | 2025 | |
| Amgen INC. | $13.99 | 2019 | |
| Pfizer INC. | $13.73 | 2025 | |
| Optinose US, INC. | $13.59 | 2024 | |
| Ucb, INC. | $13.25 | 2021 | |
| Ardelyx, INC. | $12.99 | 2023 | Ibsrela |
| Sun Pharmaceutical Industries INC. | $11.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jyothi Gudla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.